Shuu-Jiun Wang (Taiwan)

Taipei Veterans General Hospital The Neurological Institute
Dr. Shuu-Jiun Wang is a practicing neurologist and Chair Professor and Vice Dean of College of Medicine and Director, Brain Research Center, National Yang Ming Chiao Tung University and Director of The Neurological Institute, Taipei Veterans General Hospital. He was the Chair of the Asian Regional Consortium of Headache from 2019 to 2021. He was President of Taiwan Neurological Society from 2017 to 2019 and founding President of the Taiwan Headache Society from 2005-2011. He serves as an associate editor of the journals Cephalalgia, Journal of Headache and Pain and others. Dr. Wang was awarded the Bruce S. Schoenberg's International Neuroepidemiology Award by AAN in 1994, the Seymour Solomon Lecture Award by the AHS in 2010, the G. Nappi Cluster Headache Award by the EHS, 5th EHMTIC in 2016 and the MacDonald-Critchley Lecture Award by the MTIS in 2020. He was also awarded Outstanding Research Award by the Ministry of Science and Technology, Taiwan in 2012 and 2018. Dr. Wang has authored more than 400 scientific papers. He is interested in clinical and neuroimaging research of different headache disorders focusing on chronic migraine, cluster headache, reversible cerebral vasoconstriction syndromes and spontaneous intracranial hypotension.

Author Of 4 Presentations

 Conference Calendar
Sponsored Symposium

Expect More: What should be the treatment expectations

Session Type
Sponsored Symposium
Session Name
640 - Parallel Industry Symposium 06 (Not Included In The Main Event CME/CPD Credit) (ID 63)
Date
04.10.2021, Monday
Session Time
14:00 - 15:00
Room
Industry 2
Lecture Time
14:05 - 14:20
Presenter
  • Shuu-Jiun Wang (Taiwan)
Sponsored Symposium

Q&A

Session Type
Sponsored Symposium
Session Name
1010 - Parallel Industry Symposium 10 (Not Included In The Main Event CME/CPD Credit) (ID 104)
Date
05.10.2021, Tuesday
Session Time
14:00 - 14:30
Room
Industry 1
Lecture Time
14:20 - 14:30
Presenter
  • Piero Barbanti (Italy)
  • Dawn Buse (United States of America)
  • Shuu-Jiun Wang (Taiwan)
Sponsored Symposium

At what point during your patient’s medical journey do you prescribe mAbs to treat the patient’s migraine?

Session Type
Sponsored Symposium
Session Name
1010 - Parallel Industry Symposium 10 (Not Included In The Main Event CME/CPD Credit) (ID 104)
Date
05.10.2021, Tuesday
Session Time
14:00 - 14:30
Room
Industry 1
Lecture Time
14:10 - 14:15
Presenter
  • Shuu-Jiun Wang (Taiwan)
Scientific Session: MT (Main Topics)

VESTIBULAR MIGRAINE

Session Type
Scientific Session: MT (Main Topics)
Session Name
140 - HEADACHE AND PAIN - ADVANCES IN OF MIGRAINE (WFN/INTERNATIONAL HEADACHE SOCIETY JOINT SESSION) (ID 32)
Date
03.10.2021, Sunday
Session Time
11:30 - 13:00
Room
Main Topic B
Lecture Time
11:53 - 12:16
Presenter
  • Shuu-Jiun Wang (Taiwan)

Abstract

Abstract Body

Vestibular Migraine

Shuu-Jiun Wang, MD

College of Medicine & Brain Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan

Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan

The prevalence of vestibular migraine (VM) ranges from 1% to 2.7%. Despite migraine and vertigo are both common disorders, a close association between vestibular symptoms and migraine is beyond coincidence. VM, a clinical entity that incorporates vestibular and migrainous symptoms, is now defined by the International Headache Society and Barany Society. According to the proposed criteria, VM is defined as a migraine patient who has episodes of moderate-to-severe vestibular symptoms, and >50% of them with migrainous headache. Diagnosis of VM depends on a thorough clinical history because there are no definitive signs nor laboratory tests. The pathophysiology still remains unknown. However, based on current understanding of migraine pathophysiology, the main hypothesis focuses on the connections between trigeminal-vascular system, vestibular system, thalamus, and associated cortices. The theory is supported by recent evidence from human functional neuroimaging studies and animal studies. There is still no consensus on how to treat this group of patients due to the lack of strong evidence. Most patients only need symptomatic treatment during attacks of vestibular symptoms. For acute treatment, triptans, anti-histamines, anti-emetic agents, or even steroids can be used. For preventive treatment, calcium channel blockers (such as flunarizine), and antidepressants may be considered. In addition, vestibular rehabilitation may also be effective.

Hide

Presenter of 4 Presentations

 Conference Calendar
Sponsored Symposium

Expect More: What should be the treatment expectations

Session Type
Sponsored Symposium
Session Name
640 - Parallel Industry Symposium 06 (Not Included In The Main Event CME/CPD Credit) (ID 63)
Date
04.10.2021, Monday
Session Time
14:00 - 15:00
Room
Industry 2
Lecture Time
14:05 - 14:20
Presenter
  • Shuu-Jiun Wang (Taiwan)
Sponsored Symposium

Q&A

Session Type
Sponsored Symposium
Session Name
1010 - Parallel Industry Symposium 10 (Not Included In The Main Event CME/CPD Credit) (ID 104)
Date
05.10.2021, Tuesday
Session Time
14:00 - 14:30
Room
Industry 1
Lecture Time
14:20 - 14:30
Presenter
  • Piero Barbanti (Italy)
  • Dawn Buse (United States of America)
  • Shuu-Jiun Wang (Taiwan)
Sponsored Symposium

At what point during your patient’s medical journey do you prescribe mAbs to treat the patient’s migraine?

Session Type
Sponsored Symposium
Session Name
1010 - Parallel Industry Symposium 10 (Not Included In The Main Event CME/CPD Credit) (ID 104)
Date
05.10.2021, Tuesday
Session Time
14:00 - 14:30
Room
Industry 1
Lecture Time
14:10 - 14:15
Presenter
  • Shuu-Jiun Wang (Taiwan)
Scientific Session: MT (Main Topics)

VESTIBULAR MIGRAINE

Session Type
Scientific Session: MT (Main Topics)
Session Name
140 - HEADACHE AND PAIN - ADVANCES IN OF MIGRAINE (WFN/INTERNATIONAL HEADACHE SOCIETY JOINT SESSION) (ID 32)
Date
03.10.2021, Sunday
Session Time
11:30 - 13:00
Room
Main Topic B
Lecture Time
11:53 - 12:16
Presenter
  • Shuu-Jiun Wang (Taiwan)

Abstract

Abstract Body

Vestibular Migraine

Shuu-Jiun Wang, MD

College of Medicine & Brain Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan

Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan

The prevalence of vestibular migraine (VM) ranges from 1% to 2.7%. Despite migraine and vertigo are both common disorders, a close association between vestibular symptoms and migraine is beyond coincidence. VM, a clinical entity that incorporates vestibular and migrainous symptoms, is now defined by the International Headache Society and Barany Society. According to the proposed criteria, VM is defined as a migraine patient who has episodes of moderate-to-severe vestibular symptoms, and >50% of them with migrainous headache. Diagnosis of VM depends on a thorough clinical history because there are no definitive signs nor laboratory tests. The pathophysiology still remains unknown. However, based on current understanding of migraine pathophysiology, the main hypothesis focuses on the connections between trigeminal-vascular system, vestibular system, thalamus, and associated cortices. The theory is supported by recent evidence from human functional neuroimaging studies and animal studies. There is still no consensus on how to treat this group of patients due to the lack of strong evidence. Most patients only need symptomatic treatment during attacks of vestibular symptoms. For acute treatment, triptans, anti-histamines, anti-emetic agents, or even steroids can be used. For preventive treatment, calcium channel blockers (such as flunarizine), and antidepressants may be considered. In addition, vestibular rehabilitation may also be effective.

Hide

Moderator of 1 Session

 Conference Calendar
Scientific Session: MT (Main Topics)

HEADACHE AND PAIN - ADVANCES IN OF MIGRAINE (WFN/INTERNATIONAL HEADACHE SOCIETY JOINT SESSION)

Session Time
11:30 - 13:00
Room
Main Topic B
Chair(s)
  • Shuu-Jiun Wang (Taiwan)